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Objective. Review the literature on positive peritoneal cytology in endometrioid endometrial
adenocarcinoma, its prognostic value, proposed treatment strategies, and future avenues of investigation.
Methods. PubMed search of articles pertaining to stage IIIA endometrioid endometrial adenocarcinoma
identiﬁed over 50 articles that were reviewed. Low-risk stage IIIA1 was deﬁned as those with grade 1 or 2
disease, no evidence of cervical involvement, myometrial invasion less than 50% and no lymph vascular space
invasion (LVSI). Analysis of available data was completed with weighted averages, Student's-t-test and Chi
square statistical analyses.Results. Incidence of positive washings is approximately 11%. In low-risk stage IIIA1 endometrial
carcinoma patients, the rate of recurrence is 4.1%. In contrast, in high-risk stage IIIA1 endometrial carcinoma
patients the rate of recurrence is 32%, a statistically signiﬁcant difference (pb0.001). Positive peritoneal
cytology is associated with an increased incidence of extrauterine disease but is not consistently linked to
other high-risk factors such as positive lymph node status, extent of myometrial invasion or LVSI.
Conclusions. To date there is no deﬁnitive consensus on the prognostic signiﬁcance of positive peritoneal
cytology alone. However, even in the low-risk cohort with stage IIIA1 some patients will recur. Adjuvant
therapy for low-risk stage IIIA diseased may or may not be of beneﬁt. High-risk disease should be treated
with chemotherapy, radiation or a combination thereof. A prospective, multicenter trial of comprehensively
surgically staged patients with stage IIIA endometrial cancer is indicated in order to clearly deﬁne prognosis
and treatment for these patients.© 2009 Elsevier Inc. Open access under CC BY-NC-ND license.IntroductionDeﬁning the prognosis and treatment of stage IIIA carcinoma of the
uterus has been an elusive task. The current treatment options are
disparate and range from observation to aggressive multi-modal
therapy. This paper reviews the current literature and attempts to
resolve both the vexing prognostic and treatment dilemmas inherent
in this sub-stage of uterine malignancies. Contemporary management
of endometrial cancer has witnessed signiﬁcant change as traditional
modes of management have been altered, and novel approaches have
emerged. The largest areas of change have been in the initial surgical
approach and choice of adjuvant therapy for these patients.
Additionally, progress has been made in deﬁning the molecular
pathogenesis of this cancer including the association with Lynch
syndrome.
An estimated 40,100 cases of endometrial cancer will be diagnosed
in the United States in 2008 resulting in 7470 deaths [1]. Numerous
risk factors have been identiﬁed, including unopposed estrogen-NC-ND license.exposure, late menopause, obesity, nulliparity, diabetes, estrogen-
secreting ovarian tumors, polycystic ovarian syndrome, anovulation,
and tamoxifen administration [2]. From 1987 to 1998, the number of
endometrial cancer deaths doubled and continues to increase, despite
a relatively stable incidence of disease. Fortunately because patients
often present early with postmenopausal bleeding, nearly 75% of cases
are conﬁned to the uterus (stage I) at the time of diagnosis and these
patients demonstrate ﬁve-year survival rates of approximately 95%.
Survival decreases to 67% and 23%, respectively, for those with
regional or distant disease [1,3].
Stage III uterine cancer comprises a very heterogeneous group of
patients. It includes women with positive peritoneal cytology being
the only manifestation of extra-uterine extension (stage IIIA1 or
“cytological” IIIA); uterine serosal or adnexal involvement (stage IIIA2
or “histological” IIIA); vaginal metastasis (stage IIIB); and positive
retroperitoneal lymph nodes (stage IIIC). Stage IIIA incidence is 5–20%,
and survival is 60–100% depending upon associated factors [4–6].
Consensus for optimal management has been elusive in stage III
disease. The relative paucity of robust data that exists after sub-
stratiﬁcation has precluded the conduct of well-designed clinical trials
in these distinct cohorts. This article reviews the literature on positive
Table 1
Rates of positive peritoneal cytology in a number of large or landmark studies.
Author Total number of patients Overall (%) Stage I (%) Stage II (%) Stage III (%) Stage IV (%) Grade 1 (%) Grade 2 (%) Grade 3 (%)
Creasman et al. [7] 183 11.50 15.50 n/a n/a n/a 9 22 16
Imachi et al. [8] 61 23 14.30 21.10 50 80 11 7 17
Kashimura et al. [9] 303 15 9 25 24 50 11 20 17
Kennedy et al. [10] 163 5.50 n/a n/a n/a n/a n/a n/a n/a
Kennedy et al. [11] 270 5.20 n/a n/a n/a n/a n/a n/a n/a
Konski et al. [12] 134 14.00 11 66 100 n/a n/a n/a n/a
Lurain et al. [13] 157 19 n/a n/a n/a n/a 13 21 32
Mazurka et al. [14] 253 6.30 n/a n/a n/a n/a 5% 6% 13%
Sutton [15] 340 21.20 17.10 19.50 68.70 85.70 n/a n/a n/a
Turner et al. [16] 567 4.90 n/a n/a n/a n/a n/a n/a n/a
Yazigi et al. [17] 93 11 n/a n/a n/a n/a 11 7 17
Milosevic (review) [18] 3820 11 n/a n/a n/a n/a 8.30 12.10 15.90
McLellan (review) [19] 3091 11.40 n/a n/a n/a n/a 9.50 10.90 18.10
Table 2
Outline of conclusions made in 8 major studies regarding the association of peritoneal
cytology and high-risk uterine factors.
Author Association of peritoneal cytology and high-risk
uterine factors
Summary of conclusions
Kadar et al. [25] Positive association with high grade, LVSI
Kashimura et al. [9] Positive association with myometrial invasion N 50%
No association with FIGO grade
Gu et al. [26] No association with FIGO grade, depth of myometrial
invasion, LVSI
Obermair et al. [24] No association with FIGO grade or myometrial invasion
Takeshima et al. [27] No association with grade or depth of invasion
Fadare et al. [28] No association with myometrial invasion LVSI)
Saga et al. [23] No association with grade, depth of myometrial invasion
Havrilesky et al. [29] Positive association with depth of myometriral invasion
No association with FIGO grade
19S.L. Wethington et al. / Gynecologic Oncology 115 (2009) 18–25peritoneal cytology in endometrioid endometrial adenocarcinoma, its
prognostic value, proposed treatment strategies, and future avenues
of investigation.
Materials and methods
A search of Medline (through PubMed), Evidence Based Medicine
Reviews using Ovid and the Cochrane Central Register of Controlled
Trials was conducted to identify articles pertaining to the prognosis of
stage IIIA endometrioid endometrial adenocarcinoma. Search terms
used were endometrial carcinoma, endometrial cancer, peritoneal
cytology and prognosis. All publications were in English and were
original reports. Randomized and nonrandomized trials as well as
retrospective reviews were included. This search identiﬁed 244
articles. Articles were ﬁltered to identify only those with information
regarding prognostic value of positive cytology. The references for
each article were also examined and experts in the ﬁeld were queried
regarding additional published or unpublished sources of data. For the
purpose of our analysis “low-risk” is deﬁned as a patient with stage I
endometrioid endometrial carcinoma that is FIGO grade 1 or 2 with
less than 50% invasion, no LVSI and no cervical involvement. Stage
IIIA1 endometrial carcinoma patients are those who meet criteria for
stage IIIA with only positive peritoneal cytology and no evidence of
serosal or adnexal involvement. Stage IIIA2 patients are deﬁned as
those with histologically conﬁrmed uterine serosal or adnexal disease.
Each study was then reviewed for purposes of identifying the subsets
of patients with low-risk and high-risk disease. Analysis of available
data was completed with weighted averages, Student's-t-test and Chi
square statistical analyses.
Results
Positive peritoneal cytology is found in approximately 11% of
endometrial cancer patients (range 4.9–21.2%). This ﬁgure spans all
coincident risk factor groups including extrauterine disease, lymph
vascular space invasion, myometrial invasion greater than 50%, and
grade 3 disease. Table 1 summarizes the rates of positive peritoneal
cytology in a number of large or landmark studies [7–17]. As
demonstrated in Table 1, the incidence of positive cytology approxi-
mately doubles when associated with grade 3 histology versus grades
1 and 2. The heterogeneity of this populationmakes it difﬁcult to draw
broad based conclusions. Therefore, review of speciﬁc populations will
be undertaken: those with occult extrauterine disease, high-risk
uterine factors, otherwise stage I disease, and those with advanced
stage disease.
Is positive peritoneal cytology a predictor of occult extrauterine disease?
Taskiran and coworkers reported the largest series of stage I–III
patients evaluating the predictability of retroperitoneal lymph nodemetastasis using clinicopathologic variables since the landmark work
published by Creasman et al. [20,21]. They included only comprehen-
sively surgically staged patients, consisting of total or radical
hysterectomy, bilateral salpingo-oophorectomy, peritoneal cytology,
complete pelvic and periaortic lymphadenectomy, infracolic omen-
tectomy, and washings. After performing univariate and multivariate
analyses including histology, myometrial invasion, LVSI, peritoneal
cytology, and serosal, adnexal and cervical involvement, positive
peritoneal cytology appeared to be an independent predictive factor
for positive retroperitoneal nodal disease. More recently, Fujiwara
reported that the incidence of omental involvement was signiﬁcantly
higher in patients with positive peritoneal cytology. He also included
only surgically staged patients [22].
These ﬁndings clearly show that positive peritoneal cytology is
associated with an increased incidence of extrauterine disease. This
observation has clinical management implications as a patient with
positive washings as the unique evidence of extrauterine spread, may
beneﬁt from restaging if this was not performed initially to best tailor
adjuvant therapy.
Is positive peritoneal cytology associated with local (uterine) high-risk
factors?
In recent years, multiple groups have shown that there is not a
constant association between peritoneal washings and high-risk
uterine features. Table 2 outlines the conclusions of these publications
pertaining to the association of peritoneal cytology and high-risk
uterine factors [9,23–29]. For example, Gu and coworkers found no
differences in histological grade, depth of myometrial invasion and
LVSI between cytology-positive and cytology-negative patients in a
cohort of 298 stage I–IV women [26]. Since then Obermair, Takeshima,
Kasamatsu, and Saga have reached the same conclusions
[23,24,27,30–32].
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differentiated and deeper in myometrial invasion, but it was not
explicitly stated if this association reached statistical signiﬁcance
[33,34]. In one of the most recent studies, Havrilesky reported that
positive washings were signiﬁcantly linked to deep myometrial
invasion but, again, a positive correlation with others variables, such
as age and tumor grade was not identiﬁed [29].
Thus the majority of the most recent evidence fails to conﬁrm a
strong and consistent association between positive peritoneal cytol-
ogy and high-risk uterine factors, a fact that further emphasizes the
importance of complete surgical staging in cytology-positive patients
[9,23–29].
Is positive peritoneal cytology an independent adverse prognostic factor
in patients with otherwise early stage disease?
This critical question has no answer as to date there has never
been an ideal prospective analysis with adequate statistical power
and long-term follow-up from which ﬁrm conclusions could be
drawn. Many studies lacked uniform comprehensive surgical staging
with adequate nodal sampling, and some older studies routinely
administered preoperative radiation. Still other studies, while more
contemporary, failed to uniformly prescribe postoperative adjuvant
therapy. Described below is the evidence supporting the premise
that positive cytology is an adverse prognostic factor in otherwise
uterine conﬁned disease followed by data that fails to validate this
contention. These studies showed a recurrence rate of 17% in a total
of 145 patients. Patients were treated with chemotherapy, radiation
or combination thereof in 48% of cases. This data is summarized in
Table 3 [9,23,24,27,28,34–37].
Positive peritoneal cytology: an adverse prognostic factor
In the earliest study on prognostic implications of peritoneal
cytology, Creasman et al. published the outcomes of 13 patients with
malignant cells in the peritoneal washings, but no “histological”
disease outside the uterus (“cytological” IIIA). During the follow-up,
46% died of disseminated intra-peritoneal carcinomatosis. Interest-
ingly, this result was similar when compared to those with “histolo-
gical” extrauterine spread at diagnosis (54%). On the basis of the poor
survival of cytology-positive patients, a plan of treating such patients
with intra-peritoneal radioactive chromic phosphate suspension (P-
32) was instituted. Twenty-three subsequent patients with clinical
stage I disease were found to have malignant cells in the peritoneal
ﬂuid. All 23 received intra-abdominal P-32 suspension instillation after
operation. There were 3 recurrences with 2 patients dying of disease.
Thus, a signiﬁcant improvement in survival was associated with P-32
use in cytology positive patients, yet the numbers overall are small
thus precluding deﬁnitive conclusions of beneﬁt [7].
Additional studies have validated these preliminary ﬁndings
[9,23,24,29]. Saga et al. retrospectively analyzed the oncologic
outcomes of 32 cytology-positive patients with endometrioid histol-
ogy who were fully surgically staged with otherwise uterine conﬁned
disease. Once again, it was seen that this subgroup behaves
signiﬁcantly worse versus those with negative washings, even after
administration of at least 3 cycles of platinum-based combination
chemotherapy. Importantly, all fatal recurrences were intra-perito-
neal. They concluded that peritoneal cytology was an independent
adverse prognostic factor [23].
Haverilesky et al. sought to identify differences in outcomes for
stage IIIA endometrial cancer patients based on pathology and
treatment. The series included 37 patients with positive cytology
only and 20 patients with adnexal or serosal involvement. These
subgroups were compared with each other as well as to 467 patients
with surgical stage I/II disease. Eighty-nine percent of the IIIA cases
received adjuvant treatment, mainly radiotherapy. No difference insurvival was seen between those with positive cytology and those
with adnexal or serosal disease, 62% versus 68% respectively. However,
both groups demonstrated worse survival compared to those with
early stage tumors. They concluded that positive peritoneal cytology
conferred a poor prognosis not unlike those with serosal invasion and
adnexal metastasis. Multivariate analysis supported aworse prognosis
for patients with positive cytology compared to those with negative
cytology [29].
Most recently, in an abstract published at the 2009 Society of
Gynecologic Oncologists (SGO) 40th Annual Meeting, a multicenter
retrospective analysis of patients who had undergone full surgical
staging and were found to have stage IIIa disease demonstrated
comparable outcomes for stage IIIA1 and stage IIIA2 patients. Follow-
up was a medium of 4.4 years with 77% overall survival for stage IIIA1
and 75% for stage IIIA2. Of note there was a statistically signiﬁcant
difference in adjuvant therapy rates. The group did however identify a
subset of stage IIIA1 patients with low-risk factors who have excellent
prognosis, 4.2% rate of recurrence [35].
Positive peritoneal cytology: not an independent prognostic factor
In contrast to the previously summarized data, other studies have
suggested that positive peritoneal cytology does not confer poor
prognosis for otherwise uterine conﬁned disease.
In a series of 534 women Takeshima et al. found that positive
peritoneal cytology carried a worse prognosis only in patients who
exhibited high-risk uterine factors simultaneously, such as poorly
differentiated tumors and deep myometrial invasion. In isolation,
positive cytology did not confer a worse prognosis [27]. Likewise,
Kasamatsu analyzed 280 patients with endometrial carcinoma
pathologically conﬁned to the uterus. Of note, only 61% had lymph
node sampling. Three-year disease free survival was 94% for patients
with negative cytology and 90% for those with positive cytology. The
study also concluded that positive cytology does not impact outcome
in patients with no other evidence of extrauterine disease [32].
Mariani et al., in a study assessing the outcomes and prognostic
factors in stage IIIA endometrial cancer, showed that the presence of
a positive peritoneal cytology was not necessarily associated with a
poor oncologic outcome and that other high-risk features were
important in determining prognosis. There were no recurrences in
the low-risk subset of 22 patients with stage IIIA1 endometrioid
histology and absence of LVSI; however, 90% of patients received
some form of adjuvant treatment, mostly WART (77%) and external
pelvic radiotherapy (9%). In contrast those patients who did the
worst were those with grade 3 and nonendometrioid histology as
well as LVSI [36]. A subsequent analysis of 347 fully staged patients
(stages I–III) published by the same group showed positive
peritoneal cytology was an adverse prognostic factor (RR=8.67,
p=0.005) [38].
Similar results were observed by Slomovitz. As in Mariani's trial all
patients had stage IIIA endometrial cancer but they included non-
endometrioid and high-risk histologies in the overall assessment. In
the 14 patients with endometrioid histology and no other evidence of
extrauterine disease, 5-year overall survival was 78.6%. Half of the 14
patients received no further treatment after the surgical staging
procedure. In a median follow-up of 71 months there was only one
recurrence [37].
In one of the few prospective trials conducted to identify
prognostic factors associated with recurrence, Lurain et al. followed
157 patients with clinical stage I endometrial carcinoma, including all
histologies. All patients underwent hysterectomy and bilateral
salpingo-oophorectomy and 65% received selective pelvic and peri-
aortic lymphadenectomy. When the patients were surgically staged,
79% had uterine conﬁned disease, and 21% presented with evidence of
extrauterine spread. On multivariate analysis, grade 3 tumor,
advanced age, lymph node involvement and extrauterine spread
Table 3
Prognostic implications of positive peritoneal cytology in otherwise uterine conﬁned disease.
Author Number
of Patients
Study population Adjuvant treatment Percentage and type of recurrence Dise free survival Overall Survival Adverse
prognostic
factor
Kashimura et al. [9] 17 % endometrioid unknown 0% n/a n/a 80% Yes
100% surgically staged 5 years
No preoperative treatment
Obermair et al. [24] 13 100% endometrioid 53.8% brachytherapy with or without
external beam radiation (7/13)
23% (3/13) 67.3 n/a Yes
54% surgically staged - 15.4% vault 36 m ths
Unknown preoperative treatment - 7.6% lymph node
Saga et al. [23] 32 100% endometrioid 100% chemotherapy (32/32) n/a n/a 87% Yes
100% surgically staged 5 years
Unknown preoperative treatment
Havrilesky et al. [29] 37 91% endometrioid 89% (33/37) 24.3% (9/37) 56% 62% Yes
100% surgically staged - 5.4% pelvic or vault 5 ye 5 years
No preoperative treatment - 8.1% abdomen
- 74% radiation
- 8.1% distant
- 17% progestins
- 2.7% “unknown”
Takeshima et al. [27] 91 100% endometrioid 9.9% chemotherapy n/a 5 ye , No high-risk
uter factors: 98.1%
n/a Only if high
risk uterine
factors are
present
100% surgically staged 2.2% radiotherapy (11/91)
5 ye , with high-risk
uter factors: 77.5%
No preoperative treatment
Mariani et al. [36] 37 78% endometrioid 78% radiotherapy (29/37)
(radiation and IP 32P)
24.3% (9/37) - No recurrence in patients
with endometrioid histology and no LVSI
79% 86% No
71% surgically staged
- 5.4% intraabdominal
5 ye 5 years
No preoperative treatment
- 18.9% extraabdominal
End etrioid Subgroup endometrioid
96% 96%
Kasamatsu et al. [32] 48 96% endometrioid 0% 10.4% (5/48) 90% 91% No
67% surgically staged - 6% distant 36 m ths 5 years
No preoperative treatment
Tebeu et al. [34] 33 91% endometrioid 81% (27/33) n/a n/a 90.9% n/a
100% clinically staged - 42% external beam and brachytherapy
Unknown preoperative treatment - 27% external beam 5 years
- 12% brachytherapy
Slomovit et al. [37] 14 100% endometrioid 50% (7/14) n/a n/a 78.6% No
50% surgically staged - 14.3% external beam
No preoperative treatment - 28.6% brachytherapy 5 years
- 7.1% chemotherapy
Fadare et al. [28] 10 80% endometrioid 90% (9/10) 0% n/a n/a n/a
- 30% chemotherapy70% surgically staged
- 20% chemotherapy and radiation 51 months
(6–94 months)- 10% external beam and brachytherapy
No preoperative treatment
- 20% brachytherapy
- 10% progestins
Total 332 92% endometrioid 48% (155/332) 17% (25/145)
87% surgical staging
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Table 4
Rate and location of recurrence in surgically staged IIIA1 patients with low-risk factors.
Author Low-risk
patients
Number of
recurrences
Percentage of
recurrence
Most frequent site of
recurrence
Percentage of patients receiving
adjuvant treatment
Type of adjuvant treatment
administrated
Obermair et al. [24] 10 2 20% Pelvic 60% (6/10) Pelvic RT
100% (2/2) 100% (6/6)
Takeshima et al. [27] 53 1 1.8% Extraperitoneal 0% (0/53) n/a
100% (1/1)
Mariani et al. [36] 18 0 0% n/a 89% (16/18) Radiation
100% (16/16)
Slomovitz et al. [37] 6 0 0% n/a n/a
Fadare et al. [28] 5 0 0% n/a 80% (4/5) Vaginal brachytherapy
40% (2/5)
Havrilesky et al. [29] 6 1 16.6% Not speciﬁed 83% (5/6) Pelvic RT
33% (2/6)
Progestin
33% (2/6)
Havrilesky et al. [35] 24 1 4.2% Not speciﬁed 50% (12/24) Chemotherapy or
radiation
Total 122 5 4.1% n/a 37.1% (43/116) n/a
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prognostic factors. Presence of positive peritoneal cytology did not
achieve statistical signiﬁcance as a poor prognostic factor. However,
since only one ﬁfth of these patients had advanced disease at
diagnosis, this study is underpowered to deﬁnitively determine if a
positive peritoneal cytology is an adverse prognostic factor [13].
Summary of information regarding positive peritoneal cytology in
patients with stage IIIA1 endometrial carcinoma
In completely staged low-risk stage IIIA1 patients, the rate of
recurrence based on pooled data is 4.1%. This is demonstrated in
Table 4 [24,27–29,35–37]. Low-risk patients are those with grade 1 or
2 disease, no evidence of cervical involvement, myometrial invasion
less than 50% and no lymph vascular space invasion. Use of adjuvant
therapy with radiation, chemotherapy and progestin occurred in 37.1%
of patients. The high rate of adjuvant therapy confounds the results in
terms of predicting the risk of recurrence when these patients are not
treated. In a large trial with complete results regarding treatment,
Takeshima et al. had a 1.8% rate of recurrence in a group of 53
completely surgically staged patients who received no adjuvant
chemotherapy [27].
A similar evaluation of those patients with high-risk factors found
on pathology is given in Table 5 and reveals a signiﬁcantly elevated
rate of recurrence, 32%, despite an even higher rate of use of adjuvant
therapy [24,28,29,36,37]. When the pooled recurrence rates for the
low-risk (122 patients) and high-risk (60 patients) populations are
compared, there is a statistically signiﬁcant difference (pb0.001).Table 5
Rate and location of recurrence in surgically staged IIIA1 patients with high-risk factors.
Author High-risk
patients
Recurrences Percentage
Obermair et al. [22] 3 1 33.3%
Mariani et al. [34] 15 9 60%
Slomovitz et al. [35] 8 1 12.5%
Fadare et al. [26] 3 0 0%
Havrilesky et al. [27] 31 8 25.8%
Total 60 19 32%Is positive peritoneal cytology a prognostic factor in advanced
stage disease?
A number of studies have demonstrated that positive peritoneal
cytology is of prognostic signiﬁcance in the context of advanced
endometrial cancer.
Takeshima observed that in advanced endometrial cancer (deﬁned
by nodal or adnexal involvement, or peritoneal implants), patients
with positive peritoneal cytology had a statistically signiﬁcant worse
prognosis versus cytology negative patients (5-year DFS of 42.9%
versus 72.1%, respectively (p=0.015)) [27]. Similar results were
reported by Santala et al., in a retrospective analysis including 44
patients with stages II–IVB. With a median follow-up of 54 months,
they showed that positive peritoneal cytology was an independent
prognostic factor [39].
Finally, since the vast majority of advanced endometrial cancer
patients will receive adjuvant therapy, the question regarding the
prognostic value of peritoneal cytology in this cohort is largely
academic. The true clinical dilemma relates to its meaning in early
stage disease, as formerly discussed, where the role of adjuvant
therapy is unclear.Endometrial carcinoma involving the adnexa or uterine serosa
(“histological” IIIA, IIIA2)
More widespread consensus exists regarding the poor prognosis of
adnexal and serosal disease in endometrial carcinoma and the needMost frequent
recurrence's site
Adjuvant treatment Main type of adjuvant
treatment administrated
Retroperitoneal 100% (3/3) Pelvic RT
100% (1/1) 100% (3/3)
Extra-abdominal 80% (12/15) Whole abdominal
irradiation or 32P77.8% (7/9)
Abdomen n/a Vaginal brachytherapy
100% (1/1)
n/a 100% (3/3) Chemotherapy
66.6% (2/3)
Intraperitoneal Over 80% Mainly RDT
37.5% (3/8)
Extra-abdominal
37.5% (3/8)
n/a 85.7% (18/21) n/a
Fig. 1. Diagnostic and treatment algorithm for patients with stage IIIA endometrial cancer.
23S.L. Wethington et al. / Gynecologic Oncology 115 (2009) 18–25for additional treatment. However, the optimal treatment regimen is
still undetermined.
Tebeu as well as Havrilesky reported that IIIA2 patients have a
signiﬁcantly worse prognosis than those affected by disease conﬁned
to uterus. Furthermore, adnexal and uterine serosal involvement are
independent poor prognostic factors in stage III disease, with regard to
both recurrence free and overall survival. This relationship is
maintained even when adjusted for adjuvant therapy and lymph
node metastasis. Multiple modalities (radiation, chemotherapy and
hormonal therapy) have been administered with no clear documen-
ted efﬁcacy [29,34].
In dissenting opinions, Connell et al. reported that adnexal
involvement is not an independent adverse prognostic factor when
adjusted by others high-risk features such as high grade, LVSI, and
other sites of extrauterine disease [40]. Similarly, Ayhan, in an
analysis of the treatments outcomes, prognostic factors and failure
patterns of 68 surgically staged stage III patients, showed that only
high histological grade and positive peritoneal cytology performed as
independent prognostic variables [41]. Finally, Gemer et al. ques-
tioned the routine removal of ovaries during endometrial cancer
surgery. They reported that the risk of ovarian metastasis in women
with well to moderately differentiated endometrial cancer, myome-
trial invasion limited to less than one half of the myometrium,
negative peritoneal cytology and no lymph node spread is negligible.
Thus, some young patients with favorable histologies may be
candidates for ovarian preservation when future fertility via ad-
vanced technologies is desired [42].
Treatment options and recommendations
Given this background of limited deﬁnitive information on
prognosis for patients with stage IIIA1 endometrial cancer, a wide
range of recommendations have been issued regarding post operative
treatment ranging from no treatment to radiation therapy (pelvic or
abdominal), chemotherapy, hormonal therapy, or multiple modalities
in combination. Data from GOG 122 and other recent trials, supports
improved outcomes in advanced disease with chemotherapy in
comparison to whole abdominal radiation but the trial does not
address stage IIIA in speciﬁc [43]. Furthermore, the pattern ofrecurrence for patients with positive cytology indicates that coverage
beyond the pelvis alone is indicated as a signiﬁcant number of patients
have intraperitoneal sites that include the upper abdomen.
The National Comprehensive Cancer Network recommended that
patients who have had complete surgical staging including lymph
node dissection and are found to have positive cytology as the only
evidence of extrauterine disease, observation if grades 1 and 2 disease
and for grade 3 histology, one of three options: observation, vaginal
brachytherapy, or pelvic radiationwith or without vaginal brachyther-
apy. The treatment algorithm is different if the patient qualiﬁes as
stage IIIA based on ovarianmetastasis or serosal involvementwhereby
chemotherapy, radiation or both are recommended [3].
In a survey of the Society of Gynecologic Oncologists, Lee et al.
compiled data on practice patterns for 53% of the members
demonstrating signiﬁcantly varied recommendations for positive
cytology. For patients with stage IIIA by positive peritoneal cytology
alone and grade 1, 2 or 3 disease 46%, 62%, and 98% of practitioners
would recommend adjuvant therapy, respectively. In contrast, 98% of
members would recommend chemotherapy or radiation for patients
who have stage IIIA2 disease. Interestingly, one-third of respondents
believed positive cytology should remain a component of the staging
criteria [44].
Recent discussion as to the impact of positive cytology in changing
treatment protocols has raised the question of whether peritoneal
cytology should be included in the staging system. The implication of a
survey where only one-third of physicians felt that positive cytology
should remain a component of the staging system is that two-thirds
felt it should be eliminated from the criteria. The Gynecologic Cancer
Intergroup recommended to FIGO that the staging system no longer
include peritoneal cytology given the limited evidence that it alters
treatment planning. The International Federation of Gynecology and
Obstetrics ﬁnal decision is pending [45].
Discussion
Review of the available literature as outlined in this article results
in several conclusions that may be used to guide treatment decisions.
First, positive peritoneal cytology occurs in approximately 11% of
patients with endometrial cancer. Second, it is associated with an
24 S.L. Wethington et al. / Gynecologic Oncology 115 (2009) 18–25increased incidence of extrauterine disease; and in those with
extrauterine disease, presence of positive peritoneal cytology rarely
alters management. Third, positive peritoneal cytology is not
consistently linked to other high-risk factors as seen in multiple,
large contemporary studies. This lack of connection supports the
importance of complete surgical staging including peritoneal cytology
and lymph node dissection.
Lastly, there is no deﬁnitive consensus on the prognostic
signiﬁcance of positive peritoneal cytology when disease is otherwise
conﬁned to the uterus. There is in an incomplete understanding of the
basic biology and metastatic potential of positive cytology. Our initial
bias was that a low-risk group of stage IIIA1 patients could be
identiﬁed who when fully surgically staged would not require
adjuvant treatment. However, deﬁning this subgroup has been
difﬁcult even after contacting multiple authors of the large studies
for additional clariﬁcation. Pooled analysis revealed 122 low-risk
patients with a recurrence risk of 4.1%. Treatment may not be required
in this cohort; however, there is no single study of sufﬁcient power
and follow-up that demonstrates no risk of recurrence. Furthermore,
the clinical beneﬁt of adjuvant treatment in patients with such a
low-risk of recurrence remains unproven as the magnitude of effect
adjuvant therapy has on outcome is undeﬁned.
Discussion of the role of positive cytology in outcome ultimately
comes back to discussion of malignant potential of peritoneal cells and
biologically plausible theories of disease spread. Proposed theories to
explain how malignant cells ultimately reach the abdominal cavity
include: transtubal transport, lymphatic drainage, direct extension,
hematogenous spread, and multifocal origin. As a result, early works
often comment on whether the tubes were clamped at the distal end
prior to collection of the specimens, to whether the patient had
undergone hysteroscopy prior to the surgical intervention, had saline
infusion sonohysterography, or if a uterine manipulator was used
during laparoscopically performed procedures [46]. Conﬂicting data
exists regarding the role of hysteroscopy in causing dissemination of
malignant cells leading to positive peritoneal cytology at the time of
the staging. Ben-Arie and coworkers recently published a study
comparing the oncologic outcomes of patients with early endometrial
cancer diagnosed by endometrial biopsy, uterine curettage or
hysteroscopy. No statistically signiﬁcant differences in recurrence or
survival rates were found. Similar results have been reported with the
use of saline infusion sonohysterography and the placement of a
uterine manipulator during laparoscopic surgery [31,46–49].
Beyond the mechanism of spread, there remains the question of
which cells are capable of obtaining viability with implantation and
potential metastasis. If we draw from ovarian cancer and the
upstaging based on rupture of the capsule intraoperatively, one may
conclude that all cells in the washings are theoretically capable of
metastasis [50]. Initial small studies have looked at the morphology of
malignant cells in peritoneal washings and found that differences in
scalloping of the edges affected rates of recurrence [51]and that the
number of cells identiﬁed in thewashing positively correlates with the
risk of relapse [52]. These studies are limited in number and do not
provide deﬁnitive data. Ultimately, there are likely multiple molecular
factors that inﬂuence the ability of malignant cells to survive,
proliferate and invade.
Considering that there is a strong association between positive
peritoneal cytology and occult extrauterine disease, as well as a lack of
consistent correlation between positive washings and high-risk
uterine factors, and also taking into account the fact that cytologic
features could inﬂuence the “metastatic” potential of malignant cells,
a treatment paradigm for patients with “cytological” IIIA endometrial
cancer is proposed (Fig. 1). In this treatment algorithm, patients are at
low-risk of recurrence if they have been fully surgically staged with
negative pelvic lymph nodes, grade 1 or 2 disease, no cervical
invasion, b50%myometrial invasion and no LVSI. Given the low-risk of
recurrence (4.1%) seen in this population observation is a reasonableoption to offer patients. Additional research is needed to clarify
whether the morphology of the cells, the number of cells seen or the
operative approach impacts classiﬁcation as high or low-risk.
Treatment options for positive cytology include chemotherapy,
radiation and progestins. Considering that the majority of recurrences
are intraperitoneal, chemotherapy, possibly in combination with
radiation, should be considered (Fig. 1) [7,23,53]. Limited positive
data for P-32 exists. These treatment regimens are admittedly based
on theoretical mechanisms. Although GOG 122 addresses advanced
stage disease there is no data speciﬁcally deﬁning the impact of
radiation or chemotherapy on positive versus negative cytology
patients. Even more recent studies looking speciﬁcally at sequencing
of chemotherapy and radiation treatments do not speciﬁcally address
cytology positive versus negative disease. One clear conclusion from
this review is that a prospective, multicenter trial of comprehensively
surgically staged patients with stage IIIA endometrial cancer is
indicated in order to clearly deﬁne the prognosis and treatment of
this vexing clinical entity as well as to clarify whether changes are
needed to the endometrial carcinoma staging system [54,55].
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